XBiotech hatches big plans for Austin campus

Austin-based antibody-developer XBiotech has hatched some big plans for a $200 million campus that would ultimately employ some 2,000 people, according to the Austin Business Journal. The development-stage company has raised about $50 million so far and is looking for some incentives to get the project under way. Back in March, the company got a green light to launch a mid-stage study of an antibody for cachexia. Story

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.